Full text is available at the source.
Abstract
Incretin-based anti-diabetic treatments are primarily focused on central nervous system effects related to obesity and type 2 diabetes.
- Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonists are key pharmaceutical interventions for obesity and hyperglycemia.
- These treatments may significantly influence energy balance through their action on the central nervous system.
- Understanding the neural pathways involved in these pharmaceuticals is becoming increasingly important for effective therapeutic strategies.
- Recent insights into the central pathways of glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors highlight their roles in metabolic regulation.
Simplified